Sunshine Biopharma Inc (SBFM)

[shylo14]

https://sunshinebiopharma.com/assets/press/SBFM%20Press%20Release%20June%203,%202020_Coronavirus%20Patent.pdf

“The causative agent of the current COVID-19 global pandemic is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral ‘polyproteins,’ pp1a and pp1ab. One of these functional proteins is a cysteine protease referred to as the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves the viral ‘polyproteins’ at a number of specific sites thereby generating a multi-subunit protein complex termed ‘viral replicase-transcriptase’. Because of its functional indispensability in viral replication, Mpro is an attractive drug target for the development of a treatment for COVID-19 and other Coronavirus infections,” said Dr. Slilaty.